参考文献
［1］HIBI T，ITANO O，SHINODA M，et al. Liver transplantation for hepatobiliary malignancies：a new era of “Transplant Oncology” has begun［J］. Surg Today，2017，47（4）：403-415.
［2］HIBI T，SAPISOCHIN G. What is transplant oncology［J］. Surgery，2019，165（2）：281-285.
［3］SAPISOCHIN G，HIBI T，GHOBRIAL M，et al. The ILTS consensus conference on transplant oncology：setting the stage［J］. Transplantation，2020，104（6）：1119-1120.
［4］SAPISOCHIN G，JAVLE M，LERUT J，et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma：working group report from the ILTS Transplant Oncology Consensus Conference［J］. Transplantation，2020，104（6）：1125-1130.
［5］HIBI T，RELA M，EASON J D，et al. Liver transplantation for colorectal and neuroendocrine liver metastases and hep a toblastoma. Working group report from the ILTS Transplant Oncology Consensus Conference［J］. Transplantation，2020，104（6）：1131-1135.
［6］SAPISOCHIN G，HIBI T，TOSO C，et al. Transplant oncology in primary and metastatic liver tumor：principles，evidence and opportunities［J］. Ann Surg，2021，273（3）：483-493.
［7］LINE P D，DUELAND S. Liver transplantation for second ary liver tumours：the difficult balance between survival and recurrence［J］. J Hepatol，2020，73（6）：1557-1562.
［8］RAVAIOLI M. CUCCHETTI A. PINNA A D. et al. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation［J］. Sci Rep，2017，7（1）：11305.
［9］GU X Q，ZHENG W P，TENG D H，et al. Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients［J］. World J Gastroenterol，2016，22（9）：2749-2759.
［10］LAI Q，VITALE A，IESARI S，et al. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer［J］. Hepatology，2017，66（6）：1910-1919.
［11］MEHTA N，BHANGUI P，YAO F Y，et al. Liver transpla n t ation for hepatocellular carcinoma. Working group report from the ILTS Transplant Oncology Consensus Conference［J］. Transplantation，2020，104（6）：1136-1142.
［12］BERENGUER M，BURRA P，GHOBRIAL M，et al. Pos t tr ansp lant management of recipients undergoing liver tra n s plantation for hepatocellular carcinoma. Work ing group rep ort from the ILTS Transplant Oncology Con s en sus Conference［J］. Transplantation，2020，104（6）：1143-1149.
［13］ACUNA S A，HUANG J W，SCOTT A L，et al. Cancer scr e ening recommendations for solid organ transplant recip ients：a systematic review of clinical practice guid elines［J］. Am J Transplant，2017，17（1）：103-114.
［14］LERUT J，IESARI S，FOGUENNE M，et al. Hepatocellular cancer and recurrence after liver transplantation：what about the impact of immunosuppression［J］. Transl Gastroenterol Hepatol，2017，12（2）：80.
［15］KRISL J C，DOAN V P. Chemotherapy and transplantation：the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients［J］. Am J Transplant，2017，17（8）：1974-1991.
［16］KOFF J L，WALLER E K. Improving cancer-specific outcomes in solid organ transplant recipients：where to begin［J］. Cancer，2019，125（6）：838-842.
［17］MANZIA T M，ANGELICO R，GAZIA C，et al. De novo malignancies after liver transplantation：the effect of immunosuppression-personal data and review of literature［J］. World J Gastroenterol，2019，25（35）：5356-5375.
［18］RODRÍGUEZ-PERÁLVAREZ M，GUERRERO M，BARRERA L，et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation［J］. Transplantation，2018，102（12）：2056-2064.
［19］HO C M，CHEN H L，HU R H，et al. Harnessing immu no ther apy for liver recipients with hepatocellular carcinoma：a review from a transplant oncology perspective［J］. Ther Adv Med Oncol，2019，26（11）：1-11.
［20］PINTER M，SCHEINER B，PECK-RADOSAVLJEVIC M. Immunotherapy for advanced hepatocellular carcinoma：a focus on special subgroups［J］. Gut，2020，70（1）：204-214.
［21］PANCHABHAI T S，ARROSSI A V，PATIL P D，et al. Une xpected neoplasms in lungs explanted from lung trans plant recipients：a single-center experience and review of literature［J］. Transplant Proc，2018，50（1）：234-240.
［22］KEWCHAROEN J，PRASONGDEE K，SINPH U R M SU KSKUL S，et al. Recurrent cardiac myxoma treated by orthotopic heart transplantation：a case report and literat ure review of heart transplantation for primary cardiac tumor［J］. Case Rep Transplant，2018，2018：2456949.
［23］SMEDMAN T M，GUREN T K，LINE P D，et al. Tran sp lant oncology：assessment of response and tolerance to sys temic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study［J］. Transpl Int，2019，32（11）：1144-1150.
［24］NADALIN S，SETTMACHER U，RAUCHFUSS F，et al. RAPID procedure for colorectal cancer liver metastasis［J］. Int J Surg，2020，82S：93-96.
［25］D’IZARNY-GARGAS T，DURRBACH A，ZAIDAN M. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer：a systematic review ［J］. Am J Transplant，2020，20（9）：2457-2465.
［26］EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTH CARE. y and safety of organs for transplantation（7th Edition）［M］. Strasbourg：Council of EurGuide to the qualitope，2018：219-263.
［27］MATSER Y A H，TERPSTRA M L，NADALIN S，et al. Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients［J］. Am J Transplant，2018，18（7）：1810-1814.
［28］ECCHER A，GIROLAMI I，MOTTER J D，et al. Donortransmitted cancer in kidney transplant recipients：a systematic review［J］. J Nephrol，2020，33（6）：1321-1332.
［29］YANIK E L，SMITH J M，SHIELS M S，et al. Cancer risk after pediatric solid organ transplantation［J］. Pediatrics，2017，139（5）：e20163893.
［30］DIERICKX D，HABERMANN T M. Post-transplantation lymphoproliferative disorders in adults［J］. N Engl J Med，2018，378（6）：549-562.
［31］D’ARCY M E，COGHILL A E，LYNCH C F，et al. Surviv al after a cancer diagnosis among solid organ transplant recipients in the United States ［J］. Cancer，2019，125（6）：933-942.
［32］IVANICS T，PATEL M S，ERDMAN L，et al. Artificial int e lligence in transplantation（machine-learning classifiers and transplant oncology）［J］. Curr Opin Organ Transplant，2020，25（4）：426-434.